Joinn Laboratories to launch new biotech investment fund

Joinn Laboratories (China) Co., Ltd. announced a plan to partner with professional investment institutions to establish the Shenzhen Yifeng Guangming Science City Seed Fund (Limited Partnership), with a capital commitment of up to 10 million yuan. The fund will focus on strategic emerging industries, future industries, biomedicine, and high-end medical devices, aligning with the company’s long-term development strategy.

In its 2025 semi-annual report, the company reported a net profit attributable to shareholders of 60,932,399.37 yuan, alongside a pre-tax government grant of 28,852,800 yuan. The report also details the accrual of asset impairment provisions totaling 60,619,100 yuan, which includes a reversal of credit impairment losses of 5,391,400 yuan, inventory write-downs of 55,541,200 yuan, and long-term deferred expenses write-downs of 10,469,300 yuan. These provisions will reduce the net profit attributable to shareholders by 54,142,000 yuan.

The company will host a semi-annual earnings conference on September 5, 2025, to discuss these results and address investor questions. This conference will be held from 4:00 p.m. to 5:00 p.m. at the Shanghai Stock Exchange Roadshow Center.